Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (...

Descripción completa

Detalles Bibliográficos
Autores principales: Erythropoulou-Kaltsidou, Anastasia, Polychronopoulos, Georgios, Tziomalos, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965547/
https://www.ncbi.nlm.nih.gov/pubmed/31734830
http://dx.doi.org/10.1007/s13300-019-00724-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965547/
https://www.ncbi.nlm.nih.gov/pubmed/31734830
http://dx.doi.org/10.1007/s13300-019-00724-w

Ejemplares similares